Dr Régis de Albuquerque Campos joins Professor Marcus Maurer to discuss the implications of angioedema and its impact on people living with chronic spontaneous urticaria (CSU). Dr Campos highlights diverse aspects of the burden of CSU and the impact misdiagnosis has on quality of life. Professor Maurer provides an overview of the current treatment landscape, differential diagnosis, unmet needs in angioedema clinical trials and the utilisation of omalizumab in managing angioedema associated with CSU. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Utilise the following external links to access additional resources relating to the topics discussed in this episode: A Comprehensive Review of Bradykinin-Induced Angioedema Versus Histamine-Induced Angioedema in the Emergency Department, Isolated angioedema: A review of classification and update on management and The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update. Access additional resources by signing up to Medthority and to be notified for future 'All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related